Brief: Aeterna Zentaris Achieves Proof-Of-Concept For The Treatment Of Nmosd With Aim Biologicals Program
13/06/2022 13:25
June 13 (Reuters) - Aeterna Zentaris Inc AEZS.TO :
* AETERNA ZENTARIS ACHIEVES PROOF-OF-CONCEPT FOR THE
TREATMENT OF
NMOSD WITH AIM BIOLOGICALS PROGRAM
Source text for Eikon: ID:nGNX4DpBmv
Further company coverage: AEZS.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on COSCIENS Biopharma
See all newsBrief: COSCIENS Acquires Nualtis Corp
Refile: Canada's COSCIENS Biopharma Q2 net loss narrows on higher sales
Canada's COSCIENS Biopharma Q1 net income turns positive on discontinued German operations
Brief: Cosciens Biopharma Inc Not Aware Of Material Undisclosed Information Amid Recent Trading Activity
Brief: Cosciens Provides Strategic Update